Welcome to our dedicated page for COLGATE PALMOLIVE CO SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COLGATE PALMOLIVE CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COLGATE PALMOLIVE CO's regulatory disclosures and financial reporting.
COLGATE PALMOLIVE CO (CL) reported that officer Panagiotis Tsourapas, COO, CD, EMEA, APac, Skin, indirectly sold 10,000 shares of common stock on August 24, 2026 in a sale coded "S". The weighted average sale price was $92.0477 per share, with individual trades executed between $92.00 and $92.12 per share. After this transaction, an associated trust held 64,901 shares, which includes 12,661 shares that had previously been reported as directly beneficially owned. Separate holding entries show Tsourapas directly holding 9,074 shares and indirectly holding 4,619 shares through the issuer's 401(k) plan trustee.
COLGATE PALMOLIVE CO (CL) insider Panagiotis Tsourapas filed a notice of proposed sale of 10,000 shares of common stock of Colgate-Palmolive. The shares are to be sold through Merrill Lynch on the NYSE, with an aggregate market value listed as $920,477.17.
The filing also lists equity awards that will provide shares in the future, including 799 shares from vesting of restricted stock unit awards on 09/13/2024 and 9,201 shares from vesting of performance share unit awards on 02/23/2026, all granted under Colgate-Palmolive’s equity compensation plan.
Colgate-Palmolive director John T. Cahill reported an option exercise-and-sale on August 6, 2026. He exercised stock options for 4,170 shares of common stock at an exercise price of $71.56 per share and sold 4,170 shares at a weighted average price of $93.3712–$93.39, with part of the proceeds delivered to Colgate-Palmolive to pay the option exercise price. After these transactions, he continues to hold 36,357 shares indirectly through a trust.
Colgate-Palmolive Chairman, President & CEO Noel R. Wallace exercised stock options covering 322,042 shares of common stock at an exercise price of $72.2900 per share on August 4–5, 2026, then sold an equal number of shares at weighted average prices of $91.9179 and $92.5215, with a portion of the sale proceeds delivered to the issuer to pay the option exercise price and related tax withholding.
Reported indirect holdings include 54,868 shares held by the issuer's 401(k) plan trustee, 52,000 shares held by a spouse trust, and 335 shares held by another trust.
Colgate-Palmolive Co insider Noel Wallace filed a notice to potentially sell 161,021 shares of common stock through Merrill Lynch on August 5, 2026 on the NYSE. The shares relate to an exercise of employee stock options via a broker-assisted cashless exercise. The filing also lists a sale during the prior three months of 161,021 shares of common stock on August 4, 2026, with an aggregate value of $14,800,720.47.
Colgate-Palmolive Co. is the issuer in a planned resale of its common stock, with a notice covering up to 161,021 shares. The shares are to be sold through Merrill Lynch in a broker-assisted cashless exercise of employee stock options, with an indicated aggregate market value of $14,800,720.47. The securities, identified by CUSIP 797172829, are listed on the NYSE, and the proposed sale date is August 4, 2026.
Colgate-Palmolive Company reported higher Q2 2026 sales but lower GAAP earnings as major productivity-program charges weighed on results. Net sales rose 4.9% to $5,361 million, with organic sales up 2.4% on 0.9% volume growth, 1.6% pricing and 2.4% favorable foreign exchange.
Gross profit margin improved to 61.5% from 60.1%, helped by funding-the-growth cost savings and pricing, partly offset by higher raw and packaging costs. GAAP operating profit declined to $1,016 million and diluted EPS to $0.86, driven by $129 million of pre-tax charges from the Strategic Growth and Productivity Program. Excluding these and prior-year acquisition costs, operating profit increased 5% to $1,145 million and diluted EPS 8% to $0.99.
For the first half of 2026, net sales reached $10,686 million while operating cash flow strengthened to $1,742 million. Colgate has incurred $318 million of cumulative pre-tax charges under its productivity program, which is expected to total $350–$550 million and deliver projected annual pre-tax savings of $200–$300 million once fully implemented by 2028.
Colgate-Palmolive Company reported second quarter 2026 net sales of $5,361 million, up 4.9% from 2025, with organic sales growth of 2.4%. GAAP diluted EPS decreased 5% to $0.86, while non-GAAP Base Business EPS rose 8% to $0.99. GAAP and Base Business gross profit margin improved 140 basis points to 61.5%. GAAP operating profit was $1,016 million (down 6%), but non-GAAP operating profit increased 5% to $1,145 million, with a 21.4% margin.
For the first six months of 2026, net sales were $10,686 million and net income attributable to Colgate-Palmolive was $1,339 million, with diluted EPS of $1.67. Net cash provided by operations was $1,742 million, generating free cash flow before dividends of $1,476 million. Total debt was $7,857 million, with debt less cash, cash equivalents and marketable securities of $6,404 million. The company reported year-to-date global market shares of 41.3% in toothpaste and 32.7% in manual toothbrushes. For full year 2026, Colgate-Palmolive still expects net sales up 2% to 6% and organic sales growth of 1% to 4%, and now expects gross profit margin to be roughly flat on both GAAP and Base Business bases, with GAAP EPS still projected to grow at a double-digit rate and Base Business EPS at a mid-single-digit rate.